Activation of neutrophils by ANCA ("Anti-Neutrophil Cytoplasm Antibodies") and subsequent microvascular endothelial cell damage is the main feature of ANCA-associated vasculitis (AAV), a severe autoimmune disease that often targets the kidney. There is no specific treatment for AAV to date and 25% of patients with renal damage evolve towards end-stage renal disease, requiring dialysis and kidney transplantation. In addition, there is no reliable biological marker of the disease activity available, which makes the diagnostic, follow-up and treatment of patients difficult. Therefore, the identification of new therapeutic targets and non-invasive biomarkers constitutes a major clinical challenge to improve AAV patients care and to ameliorate their renal outcome.
Study Type
OBSERVATIONAL
Enrollment
63
This is a non interventional study because all levies are performed during visit planned for the care of patients.
Nantes University Hospital
Nantes, France
Expression profile of miRNAs in patients with AAV in circulating neutrophils, plasma and urine.
Time frame: 6 month after maintenance treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.